From: Identifying risk factors for L’Hermitte’s sign after IMRT for head and neck cancer
Non-LS (n = 75) | LS (n = 42) | Odds Ratio (95% CI) | p-value | |
---|---|---|---|---|
Patient characteristics | ||||
Mean age ± SD | 59.7 ± 8.7 | 56.6 ± 11.4 | 0.96 (0.93–1.01) | 0.1a |
-Difference (95% CI) | 3.1 (− 0.9 to 7) | |||
-Age range | 34–79 | 38–78 | ||
Male | 64 (85%) | 33 (79%) | 0.63 (0.3–2.2) | 0.4b |
-Difference (95% CI) | −6.7% (−21.5 to 8.1) | |||
Tumour characteristics | ||||
SCC | 68 (90.7%) | 36 (85.7%) | 0.62 (0.3–2.6) | 0.2b |
-Oropharynx | 43 (57.3%) | 26 (61.9%) | > 0.9 | |
-Oral Cavity | 9 (12.0%) | 2 (4.8%) | 0.4 | |
-Larynx | 8 (10.6%) | 2 (4.8%) | 0.4 | |
-CUP | 6 (8.0%) | 1 (2.4%) | 0.3 | |
-Hypopharynx | 1 (1.2%) | 2 (4.4%) | > 0.9 | |
-Nasopharynx | 1 (1.2%) | 3 (6.7%) | > 0.9 | |
Salivary gland | 7 (9.3%) | 6 (14.3%) | 1.6 (0.4–3.9) | > 0.9 |
Treatment plan | ||||
≥65 Gy prescribed | 60 (80.0%) | 31 (73.8%) | 0.71 (0.4–2.1) | 0.7b |
Unilateral radiotherapy | 20 (26.7%) | 18 (42.8%) | 2.06 (0.6–3.0) | 0.07b |
Cisplatin prescribed | 39 (52.0%) | 26 (61.9%) | 1.5 (0.6–2.6) | 0.3b |
-Cisplatin received | 39 (52.0%) | 24 (57.1%) | 1.23(0.5–2.3) | 0.7b |
Cetuximab prescribed | 8 (10.7%) | 2 (4.8%) | 0.42 (0.1–3.4) | 0.3b |
No chemotherapy | 28 (37.3%) | 14 (33.3%) | 0.84 (0.4–2.1) | 0.8b |
Neurological Risk Factors | ||||
Hypertension | 25 (33.3%) | 8 (19.0%) | 0.47 (0.3–1.79) | 0.1b |
Diabetes | 12 (16.0%) | 1 (2.4%) | 0.13 (0.1–3.3) | 0.03b |